Loading
Sorafenib was the first drug shown to delay progression in iodine-refractory differentiated thyroid cancer, adding about five months compared with placebo and opening the era of kinase inhibitors for the disease.
Phase 3 placebo-controlled trial of 417 patients with progressive radioactive iodine-refractory differentiated thyroid cancer randomised to sorafenib or placebo.
Median progression-free survival was 10.8 versus 5.8 months (hazard ratio 0.59) with response 12.2 versus 0.5 percent; hand-foot skin reaction, diarrhoea, alopecia and rash were common.
Sorafenib is an approved option for iodine-refractory thyroid cancer, now usually used after or instead of lenvatinib depending on tolerability.
Shares DECISION, Follicular thyroid cancer.
Shares Sorafenib, The Lancet.
Shares Follicular thyroid cancer, Sorafenib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/